Since high circulating RANKL levels have been associated with both insulin resistance and the risk of developing T2DM [24, 45], it is likely that Dmab exerts a significant effect in patients with insulin resistance due to a greater inhibition of the RANKL activity. This evidence concerns the gene TNFSF11 and Insulin resistance.